Xanax Xr

Panic Disorder, Generalized Anxiety Disorder

Treatment

16 Active Studies for Xanax Xr

What is Xanax Xr

Alprazolam

The Generic name of this drug

Treatment Summary

Alprazolam is a medication prescribed to treat anxiety and panic disorders. It should not be used with drugs that inhibit CYP3A, such as ketoconazole and itraconazole. When stopping treatment, the dose should be reduced gradually to avoid withdrawal symptoms. Side effects of Alprazolam include sedation and taking the drug with alcohol can be dangerous and lead to coma or death. Alprazolam was approved by the FDA in 1981.

Alprazolam

is the brand name

image of different drug pills on a surface

Xanax Xr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Alprazolam

Alprazolam

1981

518

Effectiveness

How Xanax Xr Affects Patients

Alprazolam is a type of medicine that impacts the brain by slowing down nerve signals. It can be dangerous to take alprazolam with opioids as it can lead to serious side effects like coma or death. People with weak respiratory systems and those using heavy machinery should avoid taking alprazolam. There is a risk of abuse and addiction with alprazolam, so it should be taken with caution. When stopping the use of alprazolam, the dose should be slowly decreased to avoid withdrawal symptoms. Newborns born to mothers taking alprazolam can experience sedation and withdrawal

How Xanax Xr works in the body

GABA receptors are special proteins found in the brain. They are responsible for sending and receiving chemical signals that control nerve activity. GABA receptors contain special sites that can be activated with certain drugs to help with anxiety, sedation, and memory issues. These sites can be activated by drugs called benzodiazepines. Exactly how benzodiazepines work is not fully understood, but it is thought that they help to keep GABA receptors in a certain shape to keep them active. There may also be up to five different sites on the GABA receptor that can be activated by benzodiazepines, each with a different effect.

When to interrupt dosage

The proposed dosage of Xanax Xr is based upon the diagnosed condition. The exact amount varies, contingent upon the method of delivery featured in the table beneath.

Condition

Dosage

Administration

Generalized Anxiety Disorder

, 1.0 mg, 2.0 mg, 3.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL

, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Kit, Solution, concentrate, Solution, concentrate - Oral

Panic Disorder

, 1.0 mg, 2.0 mg, 3.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL

, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Kit, Solution, concentrate, Solution, concentrate - Oral

Warnings

Xanax Xr Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Alprazolam may interact with Pulse Frequency

There are 20 known major drug interactions with Xanax Xr.

Common Xanax Xr Drug Interactions

Drug Name

Risk Level

Description

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Alprazolam.

Azelastine

Major

Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Alprazolam.

Carbamazepine

Major

The metabolism of Carbamazepine can be decreased when combined with Alprazolam.

Copanlisib

Major

The metabolism of Copanlisib can be decreased when combined with Alprazolam.

Xanax Xr Toxicity & Overdose Risk

Taking too much alprazolam can cause drowsiness, confusion, clumsiness, and even coma or death. Mixing alprazolam with alcohol increases the risk of an overdose. If someone overdoses on alprazolam, medical professionals may monitor their pulse, blood pressure, and breathing. Treatment may include using a stomach pump and intravenous fluids. If the person's blood pressure is too low, they may be given medication to raise it. In some cases, a drug called flumazenil can be used to block the effects of alprazolam. The toxic dose of alp

image of a doctor in a lab doing drug, clinical research

Xanax Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Xanax Xr?

47 active clinical trials are currently assessing the potential of Xanax XR for alleviating Generalized Anxiety Disorder.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Panic Disorder

13 Actively Recruiting

Not Applicable

Xanax Xr Reviews: What are patients saying about Xanax Xr?

5

Patient Review

3/5/2019

Xanax Xr for Panic Disorder

I've been taking this medication for nearly four decades and it's still just as effective as it was when I started. Only had to increase the dose once, which is great.

5

Patient Review

4/6/2015

Xanax Xr for Panic Disorder

This medication is incredibly effective at halting my panic attacks. I haven't found anything that works as quickly or efficiently for my anxiety!

5

Patient Review

3/15/2014

Xanax Xr for Panic Disorder

I took this medication four times a day as prescribed, and it worked great for me.

5

Patient Review

11/22/2013

Xanax Xr for Panic Disorder

I was really struggling with anxiety and this treatment really helped me.

4

Patient Review

3/28/2022

Xanax Xr for Panic Disorder

I find that the brand name works best for my panic attacks. Do you have a similar experience?

3.7

Patient Review

12/5/2013

Xanax Xr for Panic Disorder

If this is a time release medication, how would one go about tapering?

3.3

Patient Review

12/3/2021

Xanax Xr for Panic Disorder

I take 3mg of xanax every day, and I find that it works for a few days before the anxiety starts to come back. The 2mg dose helped for a few weeks, but now I'm back up to 3mg. I don't like how this medication is working because it feels like I'm going to be up to 5mg in no time.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about xanax xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does XR mean in Xanax?

"XR CIV is a prescription medication that contains the active ingredient alprazolam, which is a member of the benzodiazepine class of drugs that act on the central nervous system."

Answered by AI

How Strong Is Xanax XR?

"XANAX XR tablets are available in strengths of 0.5 mg, 1 mg, 2 mg, or 3 mg."

Answered by AI

How long does it take for Xanax XR to start working?

"If you take Xanax by mouth, it will be quickly absorbed into your bloodstream. The effects of Xanax should kick in within an hour. The concentration of Xanax in your blood will peak one to two hours after you take it."

Answered by AI

How often does Xanax XR release?

"Alprazolam-XR is an extended-release formulation of alprazolam that provides sustained therapeutic concentrations for 24 hours after once-daily dosing. Plasma concentrations gradually decline as the time for the next dose approaches, but still remain above therapeutic minimum levels."

Answered by AI

Clinical Trials for Xanax Xr

Image of Baylor College of Medicine in Houston, United States.

Stepped Care Treatment for Anxiety

7 - 17
All Sexes
Houston, TX

Childhood anxiety disorders (CAD) are common and impairing. Family based cognitive behavioral therapy (CBT) is efficacious in treating CAD. Yet, many children do not receive care due to barriers such as limited provider availably, high treatment costs, and constrained family resources (e.g., time). To combat these barriers, other treatment methods have been developed. The stepped care treatment models maximize resources by providing low-intensity, low-cost interventions as a first time treatment, while stepping up care for those needing more intensive treatment. Specifically, a stepped care model for CAD that begins with a parent-focus intervention has great promise to deliver efficacious and cost-effective treatment without having to engage the child. While stepped care approaches show promise in treating CAD with comparable efficacy to standard CBT, there remains a large research-to-practice gap. The stepped care model for CAD that begins with a parent-focused intervention has yet been explored, and very little is known about intervention mediators that explain mechanisms of change. This research is being done to improve the reach and quality of services using a stepped care model, offering an affordable and practical solution to the widespread gap in youth mental health care.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Image of Baylor College of Medicine in Houston, United States.

Cognitive Behavioral Therapy for Childhood Anxiety and OCD

7 - 17
All Sexes
Houston, TX

Anxiety disorders in children and adolescents are common and confer significant disability. Cognitive behavioral therapy (CBT) is the recommended treatment for youth with anxiety, yet many families cannot access CBT due to cost, practicalities of attending in-person treatment sessions, and a shortage of trained providers, especially in rural areas. To combat these barriers, other treatment methods have been developed. Previous research has shown that family-based, internet-delivered CBT (iCBT) for anxiety and OCD in youth has shown a significant reduction in anxiety symptoms. Parent-coached exposure therapy (PCET) focuses entirely on teaching parents and youth together how to address anxiety through the completion of in-session parent-coached exposures and assigning parent-coached exposure as homework in between sessions. Although both iCBT and PCET show positive results in treating pediatric anxiety in comparison to standard-care CBT, little is known about the comparative efficacy of iCBT and PCET. This research is being done to understand the comparative effectiveness of two different types of cognitive-behavioral therapy (CBT) for treating anxiety or OCD in youth.

Recruiting
Has No Placebo

Baylor College of Medicine

Have you considered Xanax Xr clinical trials?

We made a collection of clinical trials featuring Xanax Xr, we think they might fit your search criteria.
Go to Trials
Image of Bradley Hospital in East Providence, United States.

Cognitive Behavioral Therapy for Pediatric Anxiety

5 - 18
All Sexes
East Providence, RI

The purpose of this study is to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations. This process of gradually approaching feared situations is called exposure. Although CBT with exposure has the best evidence for treating anxiety disorders, not all children have equal access or respond the same way to CBT. As part of this study, patients will receive weekly CBT treatment sessions involving a combination of weekly visits with an exposure coach and one visit a month with a licensed provider (e.g., psychologist, social worker). This treatment will be delivered using one of three methods: 1) in-person (face-to-face sessions, occurring in the office and the home/community), or 2) telehealth (entirely remote sessions via web-based video conference), or 3) flexible (individualized mix of in-person and/or telehealth sessions). Eligible participants will be randomly assigned to one of these three methods. Results of this study will help determine which treatment method works best for whom. Treatment as described above will occur as part of care at partnering community care sites in Rhode Island. Providers from the following partnering community care sites will make up patient treatment teams: Blackstone Valley Community Health Care, Family Services of Rhode Island, Gateway Healthcare, Newport Mental Health, and Thrive Behavioral Health. The research study is being conducted by the Pediatric Anxiety Research Center at Brown University Health. The research team will conduct the study assessments that patients will be asked to participate in as study participants. Patients will be asked to complete assessments prior to starting treatment, at two time points during treatment, at the end of treatment, and at two timepoints 3 and 6 months following the end of treatment. Participants will be compensated for their time completing research assessments.

Recruiting
Has No Placebo

Bradley Hospital

Image of University of Michigan in Ann Arbor, United States.

Neurofeedback for Anxiety

18 - 24
All Sexes
Ann Arbor, MI

This study seeks to understand emotion regulation in those with young adults with anxiety using real-time functional magnetic resonance imaging neurofeedback, a tool that allows individuals to control brain activity. The goal of this project is to understand how receiving feedback about one's own brain activity relates to emotion regulation ability. This work will help the study team understand the brain areas involved in emotion regulation and could lay the groundwork to test if psychotherapy outcomes can be enhanced using neurofeedback. The study hypotheses include: * Participants receiving veritable-Neurofeedback (NF) will show a greater activation increases in the prefrontal cortex (PFC) compared to sham-NF * Participants receiving veritable-NF will show greater cognitive reappraisal (CR) ability compared to those receiving sham-NF * PFC activation will positively correlate with CR ability

Recruiting
Has No Placebo

University of Michigan

Stefanie Russman Block, Ph.D

Image of UT Southwestern Multispecialty Psychiatry Clinic in Dallas, United States.

Social Therapy for Eating Disorders

18 - 30
All Sexes
Dallas, TX

Social processing and cognition are often altered in patients with eating disorders. The goal of this clinical trial is to assess two different social therapeutic interventions -- one educational, one interactive -- for their effectiveness in improving clinical outcomes in patients with eating disorders. Patients in both interventions will receive education about social function in eating disorders, but those in the interactive treatment group will complete an additional collaborative art task. Participants will: * attend a baseline study visit to complete clinical interviews, cognitive testing, and behavioral tasks * complete a pre-intervention assessment with questionnaires * attend eight sessions of their assigned treatment group over the course of 12 weeks * complete three virtual follow-up assessments 4, 8, and 12 months from their baseline * attend a final study visit to repeat some clinical interviews, cognitive testing, and behavioral tasks Researchers will compare changes in eating disorder, mood, and anxiety symptoms as well as test results from baseline and final study visits for each group to see if * patients can be treated effectively with education alone or if an interactive group component produces additional benefits * cognitive and behavioral task performance are associated with recovery or illness state.

Recruiting
Has No Placebo

UT Southwestern Multispecialty Psychiatry Clinic

Carrie J McAdams, MD PhD

Image of Baylor College of Medicine in Houston, United States.

Family-Based Behavioral Therapy for Childhood Anxiety and OCD

7 - 13
All Sexes
Houston, TX

Anxiety and obsessive-compulsive disorders are among the most common in children. Although cognitive behavioral therapy (CBT) is an effective and evidence-based treatment for such disorders, access to CBT is often limited. Family-based and internet-delivered therapy is one method to increase access to care. The purpose of this project is to evaluate the comparative efficacy and treatment mechanisms of two lower-intensity but effective treatments for families of children with anxiety or obsessive compulsive disorder (OCD) via telehealth compared to an adapted Relaxation and Mentorship Training (RMT) intervention involving breathing exercises with a therapist.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Have you considered Xanax Xr clinical trials?

We made a collection of clinical trials featuring Xanax Xr, we think they might fit your search criteria.
Go to Trials
Image of Université de Sherbrooke in Sherbrooke, Canada.

Group Self-Management Support for Anxiety Disorders

18+
All Sexes
Sherbrooke, Canada

Background. Self-management support is a complementary approach to treatment that aims to educate participants on the nature of anxiety and to improve their strategies to manage symptoms and well-being, thus presenting the potential to enhance recovery, improve outcomes, reduce recurrence rates and lower health care costs. There is limited evidence to support the effectiveness of group self-management support for anxiety disorders in community-based care. Objectives. This study aims at examining the effectiveness of a virtual group self-management support program (SMS) for anxiety disorders as an add-on to treatment-as-usual (TAU) in community-based care settings. We will also assess the incremental cost/effectiveness ratio and the implementability of the intervention. Methods. The trial is a pragmatic randomized controlled trial with a pre-treatment, post-treatment (4-month post-randomization), and follow-ups at 8, 12 and 24-months. Intervention. The experimental condition will consist of a 10-week SMS program for anxiety disorders in addition to TAU. The control condition will receive TAU without restrictions for anxiety disorders. Inclusion criteria will comprise being 18 years old or older, French-speaking, and presenting symptoms of anxiety disorders based on self-reported validated assessment scales. Patients will be recruited in the province of Quebec (Canada). Outcome measures: The primary outcome measure is the Beck Anxiety Inventory (BAI). The secondary outcome measures include self-reported instruments for anxiety and depressive symptoms, recovery, self-management, quality of life, and service utilisation. Statistical analysis: Intention-to-treat analysis. A mixed effects regression model will be used to account for between and within-subject variations in the analysis of the longitudinal effects of the intervention. Expected outcomes. The rigorous evaluation of the SMS intervention in the real world will provide information to decision makers, health care managers, clinicians and patients regarding the added value of group SMS for patients with anxiety disorders. Widespread implementation of this intervention could lead to more efficient mental health care services, to better long-term outcomes and to a significant reduction in the extensive social and economic burden of anxiety disorders.

Waitlist Available
Has No Placebo

Université de Sherbrooke

Pasquale Roberge, Ph.D.

Have you considered Xanax Xr clinical trials?

We made a collection of clinical trials featuring Xanax Xr, we think they might fit your search criteria.
Go to Trials